Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05616962 · ClinicalTrials.gov registry record · NA
Vasculera in Participants With Lipedema
A NA study of Lipedema, sponsored by Primus Pharmaceuticals.
- Completed
- Registry status
- NA
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT05616962 is a NA study of Lipedema that has completed, run by Primus Pharmaceuticals. The registered enrollment target is 34 participants, below the 209-participant average among 4 other Lipedema trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05616962, a NA study of Lipedema, has completed, sponsored by Primus Pharmaceuticals.
- COMPLETED
- Registry status
- NA
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to gain preliminary information via a uniform protocol regarding the clinical effects of Vasculera in participants with lipedema and the possible role of the glycocalyx as a physiological target for Vasculera activity. It is anticipated that the results of this case study will inform the development of a formal randomized, double-blind, placebo controlled trial.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Diosmiplex
Study Locations (1)
Arizona
- Primus Pharmaceuticals - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2019-05-26 |
| Est. Completion | 2019-09-23 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05616962
The ClinicalTrials.gov registry entry for NCT05616962 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 209-participant average among 4 other Lipedema trials with a reported enrollment target (84% lower). The listed sponsor is Primus Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lipedema appearing as the primary indexed condition, and to 1 intervention - of which Diosmiplex is the first listed.
NCT05616962 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT05616962 about?
NCT05616962 is a clinical study titled "Vasculera in Participants With Lipedema". This study is designed to gain preliminary information via a uniform protocol regarding the clinical effects of Vasculera in participants with lipedema and the possible role of the glycocalyx as a physiological target for Vasculera activity. It is anticipated that the results of this case study will...
What is the current status of trial NCT05616962?
This trial is currently completed. It is a NA study. The enrollment target is 34 participants. The study started on 2019-05-26. Estimated completion is 2019-09-23.
What conditions does trial NCT05616962 study?
This clinical trial studies the following conditions: Lipedema.
What interventions are being tested in trial NCT05616962?
The interventions under investigation include: Diosmiplex (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05616962?
This trial is sponsored by Primus Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05616962 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lipedema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.